ANN ARBOR, Mich. & PHILADELPHIA--(BUSINESS WIRE)--SensiGen LLC, a biotechnology company developing advanced gene-based molecular diagnostics, announced today that it has acquired an option from the University of Michigan to exclusively license a set of epigenetic biomarkers for early detection and monitoring of Lupus. The technology includes a patented panel of proprietary biomarkers for epigenetic variations of genes uniquely associated with Lupus along with related research assays. SensiGen intends to develop commercial diagnostic assays for these novel biomarkers using the Company’s ultra-sensitive, ultra-specific AttoSense™ technology.
